Combination of an antiviral drug and immunomodulation against hepadnaviral infection in the woodchuck model

Journal of Virology

Volumn 82, Issue 5, 2008, Pages 2598-2603

  Lu, Mengji ^a   Yao, Xin ^b   Xu, Yang ^a   Lorenz, Heike ^c   Dahmen, Uta ^d   Chi, Haidong ^d   Dirsch, Olaf ^e   Kemper, Thekla ^a   He, Lifang ^b   Glebe, Dieter ^c   Gerlich, Wolfram H ^c   Wen, Yumei ^b   Roggendorf, Michael ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b FUDAN UNIVERSITY   (China)

^c JUSTUS LIEBIG UNIVERSITY   (Germany)

^d Klinik für Allgemeine Viszeral und Transplantationschirugie   (Germany)

^e Inst Pathol Cytol/Cytogenet   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; GAMMA INTERFERON; HEPATITIS ANTIBODY; HEPATITIS ANTIGEN; LAMIVUDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG WITHDRAWAL; HEPADNAVIRUS; HEPATITIS VIRUS; IMMUNIZATION; IMMUNOMODULATION; NONHUMAN; PRIORITY JOURNAL; VIRUS HEPATITIS; VIRUS LOAD; WOODCHUCK;

ANIMALS; ANTIVIRAL AGENTS; DISEASE MODELS, ANIMAL; HEPADNAVIRIDAE INFECTIONS; LAMIVUDINE; MARMOTA; PLASMIDS; VACCINES, DNA;

HEPATITIS B VIRUS; MARMOTA MONAX; WOODCHUCK HEPATITIS VIRUS;

EID: 39749112519     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.01613-07     Document Type: Article

References (46)

1. Boni, C., A. Bertoletti, A. Penna, A. Cavalli, M. Pilli, S. Urbani, and P. Scognamiglio. 1998. Lamivudine treatment can restore T cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. J. Clin. Investig. 102:968-975.
2. Boni, C., A. Penna, G. S. Ogg, A. Bertoletti, M. Pilli, C. Cavallo, and A. Cavalli. 2001. Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology 33:963-971.
3. Chisari, F. V., and C. Ferrari. 1995. Hepatitis B virus immunopathogenesis. Annu. Rev. Immunol. 13:29-60.
4. Colonno, R. J., E. V. Genovesi, I. Medina, L. Lamb, S. K. Durham, M. L. Huang, and L. Corey. 2001. Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection. J. Infect. Dis. 184:1236-1245.
5. Dahmen, U., O. Dirsch, J. Li, M. Fiedler, M. Lu, K. Rispeter, M. Picucci, C. E. Broelsch, and M. Roggendorf. 2004. Adoptive transfer of immunity: a new strategy to interfere with severe hepatitis virus reinfection after woodchuck liver transplantation. Transplantation 77:965-972.
6. Dahmen, U., J. Li, O. Dirsch, M. Fiedler, M. Lu, M. Roggendorf, and C. E. Broelsch. 2002. Liver transplantation in woodchuck: a newly established animal model of hepatitis B reinfection. Transplantation 74:374-380.
7. Dikici, B., A. G. Kalayci, F. Ozgenc, M. Bosnak, M. Davutoglu, A. Ece, and T. Ozkan. 2003. Therapeutic vaccination in the immunotolerant phase of children with chronic hepatitis B infection. Pediatr. Infect. Dis. J. 22:345-349.
8. Foster, W. K., D. S. Miller, P. L. Marion, R. J. Colonno, I. Kotlarski, and A. R. Jilbert. 2003. Entecavir therapy combined with DNA vaccination for persistent duck hepatitis B virus infection. Antimicrob. Agents Chemother. 47:2624-2635.
9. Genovesi, E. V., L. Lamb, I. Medina, D. Taylor, M. Seifer, S. Innaimo, and R. J. Colonno. 1998. Efficacy of the carbocyclic 2′- deoxyguanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection. Antimicrob. Agents Chemother. 42:3209-3217.
10. Gerlich, W. H., U. Wend, and D. Glebe. 2004. Quantitative assay of hepatitis B surface antigen in serum or plasma using Laurell electrophoresis, p. 57-63. In J. Lau and R. Hamatake (ed.), Hepatitis B virus protocols. Humana Press, Totowa, NJ.
11. Guidotti, L. G., R. Rochford, J. Chung, M. Shapiro, R. Purcell, and F. V. Chisari. 1999. Viral clearance without destruction of infected cells during acute HBV infection. Science 284:825-829.
12. Hervas-Stubbs, S., J. J. Lasarte, P. Sarobe, J. Prieto, J. M. Cullen, M. Roggendorf, and F. Borras-Cuesta. 2001. T-helper cell response to woodchuck hepatitis virus antigens after therapeutic vaccination of chronically-infected animals treated with lamivudine. J. Hepatol. 35:105-111.
13. Hervas-Stubbs, S., J. J. Lasarte, P. Sarobe, I. Vivas, L. Condreay, J. M. Cullen, and J. Prieto. 1997. Therapeutic vaccination of woodchucks against chronic woodchuck hepatitis virus infection. J. Hepatol. 27:726-737.
14. Horiike, N., S. M. Fazle Akbar, K. Michitaka, K. Joukou, K. Yamamoto, N. Kojima, and Y. Hiasa. 2003. In vivo immunization by vaccine therapy following virus suppression by lamivudine: a novel approach for treating patients with chronic hepatitis B. J. Clin. Virol. 32:156-161.
15. Ishak, K., A. Baptista, L. Bianchi, F. Callea, J. De Groote, F. Gudat, and H. Denk. 1995. Histological grading and staging of chronic hepatitis. J. Hepatol. 22:696-699.
16. Janssen, H. L., M. van Zonneveld, H. Senturk, S. Zeuzem, U. S. Akarca, Y. Cakaloglu, C. Simon, et al. 2005. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 365:123-129.
17. + T-cell proliferation response in chronic hepatitis B carriers. Vaccine 20:3598-3612.
18. Lau, G. K., T. Piratvisuth, K. X. Luo, P. Marcellin, S. Thongsawat, G. Cooksley, E. Gane, et al. 2005. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 352:2682-2695.
19. Le Guerhier, F., A. Thermet, S. Guerret, M. Chevallier, C. Jamard, C. S. Gibbs, and C. Trepo. 2003. Antiviral effect of adefovir in combination with a DNA vaccine in the duck hepatitis B virus infection model. J. Hepatol. 3:328-334.
20. Locarnini, S., and W. S. Mason. 2006. Cellular and virological mechanisms of HBV drug resistance. J. Hepatol. 44:422-431.
21. Lu, M., G. Hilken, J. Kruppenbacher, T. Kemper, R. Schirmbeck, J. Reimann, and M. Roggendorf. 1999. Immunization of woodchucks with plasmids expressing woodchuck hepatitis virus (WHV) core antigen and surface antigen suppresses WHV infection. J. Virol. 73:281-289.
22. Lu, M., M. Isogawa, Y. Xu, and G. Hilken. 2005. Immunization with the gene expressing woodchuck hepatitis virus nucleocapsid protein fused to cytotoxic-T-lymphocyte-associated antigen 4 leads to enhanced specific immune responses in mice and woodchucks. J. Virol. 79:6368-6376.
23. Lu, M., R. Klaes, S. Menne, W. Gerlich, B. Stahl, H. P. Dienes, U. Drebber, and M. Roggendorf. 2003. Induction of antibodies to the PreS region of surface antigens of woodchuck hepatitis virus (WHV) in chronic carrier woodchucks by immunizations with WHV surface antigens. J. Hepatol. 39:405-413.
24. Lu, M., S. Menne, D. Yang, Y. Xu, and M. Roggendorf. 2007. Immunomodulation as an option for the treatment of chronic hepatitis B virus infection: preclinical studies in the woodchuck model. Expert Opin. Investig. Drugs 16:787-801.
25. Lu, M., and M. Roggendorf. 2001. Evaluation of new approaches to prophylactic and therapeutic vaccinations against hepatitis B viruses in the woodchuck model. Intervirology 44:124-131.
26. Maini, M. K., C. Boni, C. K. Lee, J. R. Larrubia, S. Reignat, G. S. Ogg, A. S. King, and J. Herberg. 2000. The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J. Exp. Med. 191:1269-1280.
27. Mancini-Bourgine, M., H. Fontaine, D. Scott-Algara, S. Pol, C. Brechet, and M. L. Michel. 2004. Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers. Hepatology 40:874-882.
28. Mason, W. S., J. Cullen, G. Moraleda, J. Saputelli, C. E. Aldrich, D. S. Miller, and B. Tennant. 1998. Lamivudine therapy of WHV-infected woodchucks. Virology 245:18-32.
29. Menne, S., J. Maschke, T. K. Tolle, M. Lu, and M. Roggendorf. 1997. Characterization of T-cell response to woodchuck hepatitis virus core protein and protection of woodchucks from infection by immunization with peptides containing a T-cell epitope. J. Virol. 71:65-74.
30. Menne, S., C. A. Roneker, B. E. Korba, J. L. Gerin, B. C. Tennant, and P. J. Cote. 2002. Immunization with surface antigen vaccine alone and after treatment with 1-(2-fluoro-5-methyl-β-L-arabinofuranosyl)-uracil (L-FMAU) breaks humoral and cell-mediated immune tolerance in chronic woodchuck hepatitis virus infection. J. Virol. 76:5305-5314.
31. Pol, S., F. Driss, M. L. Michel, B. Nalpas, P. Berthelot, and C. Brechot. 1994. Specific vaccine therapy in chronic hepatitis B infection. Lancet 344:342.
32. Pol, S., B. Nalpas, F. Driss, M. L. Michel, P. Tiollais, J. Denis, and C. Brechet. 2001. Efficacy and limitations of a specific immunotherapy in chronic hepatitis B. J. Hepatol. 34:917-921.
33. Raney, A. K., R. K. Hamatake, and Z. Hong. 2003. Agents in clinical development for the treatment of chronic hepatitis B. Expert. Opin. Investig. Drugs 12:1281-1295.
34. Roggendorf, M., and M. Lu. 2005. Woodchuck hepatitis virus, p. 210-224. In T. H. Thomas, A. Zuckermann, and S. Lemon (ed.), Viral hepatitis, 3rd ed. Blackwell Publishing Ltd. Oxford, United Kingdom.
35. Roggendorf, M., I. Schulte, Y. Xu, and M. Lu. 2007. Therapeutic vaccination in chronic hepatitis B: pre-clinical studies in the woodchuck model. J. Viral Hepat. 14(Suppl. 1):51-57.
36. Rollier, C., C. Sunyach, L. Barraud, N. Madani, C. Jamard, C. Trepo, and L. Cova. 1999. Protective and therapeutic effect of DNA-based immunization against hepadnavirus large envelope protein. Gastroenterology 116:658-665.
37. Siegel, F., M. Lu, and M. Roggendorf. 2001. Coadministration of gamma interferon with DNA vaccine expressing woodchuck hepatitis virus (WHV) core antigen enhances the specific immune response and protects against WHV infection. J. Virol. 75:5036-5042.
38. + T-lymphocyte response is important for therapy-induced viral clearance in chronic hepatitis B infection. J. Hepatol. 43:45-52.
39. + T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J. Virol. 77:68-76.
40. Tolle, T. K., D. Glebe, M. Linder, D. Linder, S. Schmitt, R. Geyer, and W. H. Gerlich. 1998. Structure and glycosylation patterns of surface proteins from woodchuck hepatitis virus. J. Virol. 72:9978-9985.
41. Vandepapelière, P., G. K. Lau, G. Leroux-Roels, Y. Horsmans, E. Gane, T. Tawandee, M. I. Merican, K. M. Win, C. Trepo, G. Cooksley, M. Wettendorff, C. Ferrari, and The Therapeutic HBV Vaccine Group of Investigators. 2007. Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine. Vaccine [Epub ahead of print.] doi: 10.1016/j.vaccine.2007.09.072.
42. Wen, Y. M., X. H. Wu, D. C. Hu, Q. P. Zhang, and S. Q. Guo. 1995. Hepatitis B vaccine and anti-HBs complex as approach for vaccine therapy. Lancet 345:1575-1576.
43. Xu, D. Z., K. L. Huang, K. Zhao, L. F. Xu, N. Shi, Z. H. Yuan, and Y. M. Wen. 2005. Vaccination with recombinant HBsAg-HBIG complex in healthy adults. Vaccine 23:2658-2664.
44. Yalcin, K., M. Acar, and H. Degertekin. 2003. Specific hepatitis B vaccine therapy in inactive HBsAg carriers: a randomized controlled trial. Infection 31:221-225.
45. Yao, X., B. Zheng, J. Zhou, D. Z. Xu, K. Zhao, S. H. Sun, Z. H. Yuan, and Y. M. Wen. 2007. Therapeutic effect of hepatitis B surface antigen-antibody complex is associated with cytolytic and non-cytolytic immune responses in hepatitis B patients. Vaccine 25:1771-1779.
46. Zheng, B. J., M. H. Ng, L. F. He, X. Yao, K. W. Chan, K. Y. Yuen, and Y. M. Wen. 2001. Therapeutic efficacy of hepatitis B surface antigen-antibodies-recombinant DNA composite in HBsAg transgenic mice. Vaccine 19:4219-4225.